This series on “Targeting the DNA Damaging Pathway: PARPi and Beyond” is edited by Dr. Shaheenah Dawood, MBBCh, FACP, Department of Medical Oncology, Mediclinic City Hospital, Comprehensive Cancer Center, Dubai Health Care City, Dubai, U.A.E.
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors—proceedings from breast cancer expert group meeting
BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies
The series “Targeting the DNA Damaging Pathway: PARPi and Beyond” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Shaheenah Dawood served as the unpaid Guest Editor for the series.